Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

SLC35A2-related congenital disorder of glycosylation: Defining the phenotype

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Decline in severe spastic cerebral palsy at term in Denmark 1999-2007

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. EEG with extreme delta brush in young female with methotrexate neurotoxicity supports NMDA receptor involvement

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Neuromodulation for chronic pain and double incontinence in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clinical spectrum of STX1B-related epileptic disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Analysis of shared heritability in common disorders of the brain

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Neurodevelopmental Disorders Caused by De Novo Variants in KCNB1 Genotypes and Phenotypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Translation and Adaptation of the Genetic Counselling Outcome Scale (GCOS-24) for Use in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  • T Michael Yates
  • Mohnish Suri
  • Archana Desurkar
  • Gaetan Lesca
  • Carina Wallgren-Pettersson
  • Trine B Hammer
  • Ashok Raghavan
  • Anne-Lise Poulat
  • Rikke S Møller
  • Ann-Charlotte Thuresson
  • Meena Balasubramanian
View graph of relations

We aim to further delineate the phenotype associated with pathogenic variants in the SLC35A2 gene, and review all published literature to-date. This gene is located on the X chromosome and encodes a UDP-galactose transporter. Pathogenic variants in SLC35A2 cause a congenital disorder of glycosylation. The condition is rare, and less than twenty patients have been reported to-date. The phenotype is complex and has not been fully defined. Here, we present a series of five patients with de novo pathogenic variants in SLC35A2. The patients' phenotype includes developmental and epileptic encephalopathy with hypsarrhythmia, facial dysmorphism, severe intellectual disability, skeletal abnormalities, congenital cardiac disease and cortical visual impairment. Developmental and epileptic encephalopathy with hypsarrhythmia is present in most patients with SLC35A2 variants, and is drug-resistant in the majority of cases. Adrenocorticotropic hormone therapy may achieve partial or complete remission of seizures, but the effect is usually temporary. Isoelectric focusing of transferrins may be normal after infancy, therefore a congenital disorder of glycosylation should still be considered as a diagnosis in the presence of a suggestive phenotype. We also provide evidence that cortical visual impairment is part of the phenotypic spectrum.

Original languageEnglish
JournalEuropean journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
Volume22
Issue number6
Pages (from-to)1095-1102
Number of pages8
ISSN1090-3798
DOIs
Publication statusPublished - Nov 2018

ID: 56216619